Vera Therapeutics, Inc.
atacicept
expanded IgAN populations and other autoimmune kidney diseases
Resolved
7days ago
Phase 2 readout · ~ Jun 30, 2026 estimated
What's at stake
Phase 2 trial results for atacicept in expanded IgAN populations and other autoimmune kidney diseases are due ~ Jun 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“The eGFR results are now expected in the third quarter of 2026.”